COMMUNIQUÉS West-GlobeNewswire

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
30/05/2024
PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have [...]
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
30/05/2024
Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early onset can be expected thanks to early [...]
Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
30/05/2024
L’étude clinique réalisée en 2022 est maintenant publiée dans la revue à comité de lecture Neurology and Therapy Plus de details sur la bioéquivalence démontrée par rapport au médicament européen Dormicum® Efficacité [...]
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30/05/2024
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of [...]
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30/05/2024
Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., [...]
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
30/05/2024
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation [...]
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
30/05/2024
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu les premières doses [...]
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
30/05/2024
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI ® (INN: Piflufolastat ( 18 F) also [...]
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
30/05/2024
A clinical study, published in the journal Food Science and Nutrition, showed that GBL-Memory 1 , a unique combination of L-theanine and Fructooligosaccharides, can improve memory by up to 10.1% GBL-Memory 1 is the [...]
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
30/05/2024
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a [...]
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
30/05/2024
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May 30, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today [...]
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
30/05/2024
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
30/05/2024
Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www.inventivapharma.com Date Nombre de titres composant le capital en circulation Nombre total [...]
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
30/05/2024
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule [...]
Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
30/05/2024
Daix (France), Long Island City (New York, Etats-Unis), le 30 mai 2024 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de petites molécules [...]
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
30/05/2024
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera [...]
Merus N.V. annonce une offre publique de souscription d’actions ordinaires
30/05/2024
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 30 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie au stade clinique [...]
Nicox annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant maximum d’environ 3,8 millions d’euros
30/05/2024
Communiqué de presse Nicox annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant maximum d’environ 3,8 millions d’euros pour poursuivre le [...]
Merus Announces Pricing of Upsized Public Offering of Common Shares
30/05/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length [...]

Pages